Both in Biotechnology
Humacyte vs Coherus Oncology
Over the past year HUMA returned −69.2% and CHRS returned −45.1%; their daily moves had a correlation of 0.19.
HUMA −69.2% CHRS −45.1%Growth of $1, one year, split-adjusted
| Metric | HUMA | CHRS |
|---|---|---|
| Price | $0.4500 | $0.8502 |
| Market cap | $125.0M | $131.4M |
| Today | +2.16% | +5.54% |
| 1 month | −5.9% | −17.5% |
| 6 months | −54.2% | −51.4% |
| Year to date | −53.1% | −40.1% |
| 1 year | −71.7% | −46.9% |
| Revenue growth (YoY) | +34.9% | +39.5% |
| Gross margin | −203.2% | 70.4% |
| Net margin | −9064.5% | −144.2% |
| P/E (TTM) | — | — |
| Price / sales | 58.9× | 2.6× |
| Net cash | $13.7M | $68.1M |
| Dividend yield | — | — |
| Volatility (60d) | 107.9% | 95.4% |
| Short % of float | 11.9% | 9.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).